Previous close | 0.0100 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.0100 |
Strike | 22.00 |
Expiry date | 2024-05-03 |
Day's range | 0.0100 - 0.0100 |
Contract range | N/A |
Volume | |
Open interest | 674 |
Q1 2024 OPKO Health Inc Earnings Call
Key developments include a major asset sale and a focus on pharmaceutical innovation, despite a challenging financial quarter.
A young patient died due to cardiac arrest after receiving Pfizer's experimental gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial is testing boys 2 to three years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.